Document:

Exhibit 10.2

           December 31, 2004 Letter Agreement modifying Exhibit 10.1.

                                         1 BLUE HILL PLAZA 7TH FLOOR
                                         PEARL RIVER, NEW YORK 10989
[LOGO] PROVO
       INTERNATIONAL                 VOICE: 845.623.8553 FAX: 845.623.8669

         AMX:  FNT                        WWW.PROVOINTERNATIONAL.COM
================================================================================

December 31, 2004

Mr. Ventura Martinez del Rio, Sr.
Mr. Ventura Martinez del Rio, Jr.

         Re: Stock Purchase Agreement

Gentlemen:

      This letter agreement amends and modifies that certain Stock Purchase
Agreement dated July 14, 2004 (the "Agreement") by and among Provo
International, Inc., Ventura Martinez del Rio, Sr. and Ventura Martinez del Rio,
Jr. Capitalized terms in this letter agreement shall have the meaning ascribed
to them in the Agreement.

      1.    Article I - "Definitions" subparagraph (c) shall be deleted in its
            entirety, and shall be replaced with the following:

            "[THIS SECTION INTENTIONALLY LEFT BLANK]"

      2.    Article I - "Definitions" subparagraph (e) shall be deleted and
            replaced with the following:

            "Closing Date" shall mean March 31, 2005, or such other date as
            agreed upon, in writing, among the parties."

      3.    Section 6.01 shall be deleted in its entirety and replaced with the
            following:

            "[THIS SECTION INTENTIONALLY LEFT BLANK]"

      4.    Section 6.10 shall be deleted in its entirety and replaced with the
            following:

            "The parties agree that the closing date for financial reporting
            purposes shall be December 31, 2004. All revenue, profits and/or
            losses related to Provo Mexico operations after December 31, 2004
            shall be for the benefit and detriment of the Buyers."
<PAGE>

      5.    Section 7.01(d) shall be deleted in its entirety, and replaced with
            the following:

            "[THIS SECTION INTENTIONALLY LEFT BLANK]"

      6.    Section 7.02(d) shall be deleted in its entirety, and replaced with
            the following:

            "[THIS SECTION INTENTIONALLY LEFT BLANK]"

      7.    Section 7.01(h) shall be deleted in its entirety, and replaced with
            the following:

            "[THIS SECTION INTENTIONALLY LEFT BLANK]"

      8.    Section 7.02(h) shall be deleted in its entirety, and replaced with
            the following:

            "[THIS SECTION INTENTIONALLY LEFT BLANK]"

      9.    Section 11.01(b) shall be deleted in its entirety, and replaced with
            the following:

            "by any party if the Closing shall have not been consummated by
            March 31, 2005; provided, however, that no party may terminate this
            Agreement pursuant to this clause (b) if the Closing shall not have
            been consummated by March 31, 2005 by reason (i) of the failure of
            such party or any of its affiliates to perform in all material
            respects any of its or their respective covenants or agreements
            contained in this Agreement; or (ii) actions of a third party
            regulatory agency, in which case the aforementioned date shall be
            extended for a period of time equal to the delay caused by the
            regulatory agency."

      10.   Section 11.01(c) shall be deleted in its entirety, and replaced with
            the following:

            "[THIS SECTION INTENTIONALLY LEFT BLANK]"

      11.   Governing Law. This letter agreement shall be governed by and
            construed in accordance with the laws of the State of New York.

      12.   Confirmation of the Agreement. The Agreement, as modified by this
            letter agreement, is hereby ratified and confirmed in all respects
            by the parties hereto. The parties agree that the Agreement, as
            modified by this letter agreement, is in full force and effect, and
            is binding on and enforceable against the parties in accordance with
            its terms. All references to the "Agreement" contained in the
            Agreement shall for all purposes be deemed to refer to the Agreement
            as amended by this letter agreement.
<PAGE>

      13.   Entire Agreement; Successors Bound. This letter agreement represents
            the entire understanding of the parties. This letter agreement
            supercedes and revokes all previous negotiations, arrangements,
            letters of intent; representations, whether oral or in writing,
            between the parties with respect to the subject matter hereof. This
            letter agreement be binding upon each party's assigns, heirs and
            successors, and all others acting or claiming by through or under
            any of the parties hereto.

      Agreed to this 31st day of December, 2004:

      Provo International, Inc.

      _________________________

      Name:

      Title:

      Buyers:

      ______________________________
      Ventura Martinez del Rio, Sr.

      ______________________________
      Ventura Martinez del Rio, Jr.THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "1933 ACT"), NOR REGISTERED UNDER ANY STATE SECURITIES LAW, AND ARE "RESTRICTED SECURITIES" AS THAT TERM IS DEFINED IN RULE 144 UNDER THE 1933 ACT. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED TO THE SATISFACTION OF THE COMPANY.

ACQUISITION AGREEMENT

THIS AGREEMENT (hereinafter “the agreement”), made and entered into as of the 28th day of February, 2004 and modified on the 31st day of December, 2004, by and between Nutra Pharma Corp., a California corporation (hereinafter “Nutra Pharma”), and Receptopharm, Inc., a Nevada corporation (hereinafter “Receptopharm”), by and for the benefit of its shareholders, who, in consideration of the mutual promises and covenants contained
herein, agree as follows:

1. RECITALS:

This agreement is made and entered into with reference to the following facts and circumstances:

A. Nutra Pharma is a publicly held California corporation, with currently issued and outstanding 54,099,457 shares of common stock, whose business plan consists of the development of bio pharmaceutical products, and is the licensee of certain intellectual property, consisting of a bioactive peptide cobratoxin that has been inactivated by ozonation and that is labeled and used for treating MS or HIV, a description of which is attached hereto and incorporated by reference herein as Attachment 1 (hereinafter referred to as “the MS/HIV intellectual property.”)

B. Nutra Pharma is a publicly held and reporting company, whose securities are quoted on the NASD Over-the-Counter Bulletin Board under the trading symbol, “NPHC”.

C. Receptopharm is a privately held Nevada corporation, with 8,657,778 shares of its common stock currently issued and outstanding, who is interested in Nutra Pharma taking a significant equity position in its common stock, in order to improve its opportunities for the development of its bio pharmaceutical products and the financing of that development.

 

	
 

	 	1	 
	

	 

 

2. ACQUISITION OF RECEPTOPHARM STOCK.

In exchange for an amount of common stock to be issued by Receptopharm from its treasury pursuant to Section 4(2) of the Securities Act of 1933, which amount of common stock shall equal 4,444,444 shares, Nutra Pharma shall assign all of its right, title and interest in and to the MS/HIV intellectual property described in Attachment 1 to Receptopharm, and will contribute working capital for the development of Receptopharm, its technology and products as follows:

A. Receptopharm acknowledges receipt of $1,250,000 in capital contributions from Nutra Pharma, to be applied toward Nutra Pharma’s entire capital commitment to Receptopharm.

B. Nutra Pharma shall contribute additional capital to Receptopharm in the aggregate amount of $750,000, pursuant to the schedule (Attachment 2) attached, for a total capital commitment of $2 million.

3. POST CLOSING COVENANTS

Rik Deitsch, Nutra Pharma’s President, is a member of Receptopharm's board of directors.

4. CONDITIONS PRECEDENT TO NUTRA PHARMA’S PERFORMANCE

The acquisition of Receptopharm stock is conditioned upon the following:

A. There shall have been no material adverse change in the business or conditions (financial or otherwise) of Receptopharm since the execution of the letter of intent between the parties.

B. The representations and warranties contained in this agreement shall have been true in all material respects when made, and, in addition, shall be true and correct in all material respects as of the Closing Date, except for representations and warranties specifically relating to a time or times other than the Closing Date (which shall be true and correct in all material respects at such time or times) and except for changes contemplated and permitted by this Agreement, with the same force and effect as if made as of the Closing Date. Receptopharm shall have performed or complied in all material respects with all terms, agreements, and covenants and conditions required by this Agreement to be performed by it or prior to the Closing Date, and shall deliver a certificate of its President and Secretary or Assistant
Secretary to such effect on the Closing Date.

 

5. CONDITIONS PRECEDENT TO RECEPTOPHARM’S PERFORMANCE

	 
	 	2	 
	

	 

The acquisition of Receptopharm stock is conditioned on the following:

A. There shall have been no material adverse change in the business or conditions (financial or otherwise) of Nutra Pharma since the execution of the letter of intent between the parties.

B. The representations and warranties contained in this agreement shall have been true in all material respects when made, and, in addition, shall be true and correct in all material respects as of the Closing Date, except for representations and warranties specifically relating to a time or times other than the Closing Date (which shall be true and correct in all material respects at such time or times) and except for changes contemplated and permitted by this Agreement, with the same force and effect as if made as of the Closing Date. Nutra Pharma shall have performed or complied in all material respects with all terms, agreements, and covenants and conditions required by this Agreement to be performed by it or prior to the Closing Date.

 

6. REPRESENTATIONS AND WARRANTIES OF RECEPTOPHARM

Receptopharm hereby represents and warrants to Nutra Pharma as follows:

A. Receptopharm is a corporation duly formed and validly existing and in good standing under the laws of the state of Nevada, it has all necessary corporate powers to own its properties and carry on its business as now owned and operated by it, and is in good standing in every jurisdiction in which failure to qualify would have a material adverse affect on its business and financial condition, and has the corporate power to enter into and perform this agreement, subject only to the approval of its shareholders. Such execution, delivery and performance of this Agreement and all other instruments and documents to be delivered hereunder have been duly authorized by all necessary corporate action on the part of Receptopharm, and will not contravene or violate or constitute a breach of the terms of its Articles of
Incorporation, founding documents, or By-Laws, or conflict with, result in a breach of, or entitle any party to terminate or call a default with respect to any instrument or decree to which either is bound or any contract or any instrument, judgment, order, decree, law, rule or regulation applicable to it. Neither Receptopharm, nor their shareholders is a party to, or subject to, or bound by any judgment, injunction, or decree of any court or governmental authority or agreement which may restrict or interfere with its performance of this Agreement. This Agreement has been duly executed and delivered and constitutes, and the other instruments and documents to be delivered by Receptopharm hereunder will constitute, the valid and binding obligations of both of them, enforceable against it in accordance with their respective terms.

B. Except as otherwise set forth herein, no consent of any party to any contract or arrangement to which Receptopharm is a party or by which it is bound is required for the execution, performance, or consummation of this Agreement.

	 
	 	3	 
	

	 

C. There are no actions, suits, proceedings, orders, investigations or claims pending or, to Receptopharm’s knowledge, threatened against either one of them, at law or in equity, or before any federal, state or other governmental body, other than those disclosed in the due diligence materials.

D. The representations and warranties contained in this Section will be accurate, true and correct, in all respects, on and as of the date of Closing as though made at such date in identical language.

E. All of Receptopharm’s assets are free and clear of security interests, liens, pledges, charge and encumbrances, equities or claims, except those obligations to shareholders and others as reported on its financial statements.

F. Neither Receptopharm, nor any of its officers and directors has ever been convicted of any felony or misdemeanor offense involving moral turpitude; nor have they been the subject of any temporary or permanent restraining order resulting from unlawful transactions in securities; nor are they now, or have they ever been, a defendant in any lawsuit alleging unlawful business practices or the unlawful sale of securities; nor have they been the debtor in any proceedings, whether voluntary or involuntary, filed in the U.S. Bankruptcy Court.

G. The execution, delivery and performance of this agreement by Receptopharm does not require the consent, waiver, approval, license or authorizations of any person or public authority which has not been obtained, does not violate, with or without the giving of notice or the passage of time or both, any law applicable to either Receptopharm, and does not conflict with or result in a breach or termination of any provisions of, or constitute a default under, or result in the creation of any lien, charge or encumbrance upon any of the property or assets of Receptopharm .

H. Receptopharm has complied with all laws, ordinances, regulations and orders which have application to their respective businesses, the violation of which might have a material adverse effect on their respective financial condition or results of operations, and possesses all governmental licenses and permits material to and necessary for the conduct of their respective business, the absence of which might have a material adverse effect on their respective financial condition or results of operations. All such licenses and permits are in full force and effect, no violations are or have been recorded in respect of any such licenses or permits, and no proceeding is pending or threatened to revoke or limit any such licenses or permits.

I. The shares of common stock are owned beneficially and of record by Receptopharm’s shareholders and no other share capital of Receptopharm is issued and outstanding. There are no subscriptions, options or other agreements or commitments, obligating Receptopharm to issue any shares or securities convertible into its shares at the date of this agreement, except for options for 60,000 shares to members of the Scientific Board of Advisors, which are currently frozen, and there shall not be any others on the Closing Date.

	 
	 	4	 
	

	 

J. Receptopharm has made available to Nutra Pharma all of its audited and unaudited financial statements, all of its notes, mortgages and other obligations and agreements and other instruments for or relating to any borrowing effected by Receptopharm or to which any properties or assets of Receptopharm is subject, leases and similar agreements under which Receptopharm is subject, and a list of any and all contracts, agreements, and other instruments material to the conduct of Receptopharm’s business. Receptopharm has performed all obligations required by it to be performed under the any of the foregoing, and there has not occurred any event which with the passage of time or giving notice or both would constitute a default. 

K. Receptopharm is the owner of the intellectual property and patents pending described as set forth in Attachment 3, which is incorporated by reference herein.

 

7. REPRESENTATIONS AND WARRANTIES OF NUTRA PHARMA

Nutra Pharma hereby represents and warrants as follows:

A. Nutra Pharma is a corporation duly formed and validly existing and in good standing under the laws of the state of California, it has all necessary corporate powers to own its properties and carry on its business as now owned and operated by it, and is in good standing in every jurisdiction in which failure to qualify would have a material adverse affect on its business and financial condition, and has the corporate power to enter into and perform this agreement, subject only to the approval of its shareholders. Such execution, delivery and performance of this Agreement and all other instruments and documents to be delivered hereunder have been duly authorized by all necessary corporate action on the part of Nutra Pharma , and will not contravene or violate or constitute a breach of the terms of its Articles of
Incorporation, founding documents, or By-Laws, or conflict with, result in a breach of, or entitle any party to terminate or call a default with respect to any instrument or decree to which either is bound or any contract or any instrument, judgment, order, decree, law, rule or regulation applicable to it. Nutra Pharma is not a party to, or subject to, or bound by any judgment, injunction, or decree of any court or governmental authority or agreement which may restrict or interfere with its performance of this Agreement. This Agreement has been duly executed and delivered and constitutes, and the other instruments and documents to be delivered by Nutra Pharma hereunder will constitute, the valid and binding obligations of it, enforceable against it in accordance with their respective terms.

B. Except as otherwise set forth herein, no consent of any party to any contract or arrangement to which Nutra Pharma is a party or by which it is bound is required for the execution, performance, or consummation of this Agreement.

	 
	 	5	 
	

	 

C. The representations and warranties contained in this Section will be accurate, true and correct, in all respects, on and as of the date of Closing as though made at such date in identical language.

D. All of Nutra Pharma’s assets are free and clear of security interests, liens, pledges, charge and encumbrances, equities or claims, except those obligations to shareholders and others as reported on its financial statements.

E. Neither Nutra Pharma, nor any of its officers and directors has ever been convicted of any felony or misdemeanor offense involving moral turpitude; nor have they been the subject of any temporary or permanent restraining order resulting from unlawful transactions in securities; nor are they now, or have they ever been, a defendant in any lawsuit alleging unlawful business practices or the unlawful sale of securities; nor have they been the debtor in any proceedings, whether voluntary or involuntary, filed in the U.S. Bankruptcy Court.

F. The authorized share capital of Nutra Pharma consists of 2 billion (2,000,000,000) shares of common class stock, 54,099,457 of which are issued and outstanding, and are owned, beneficially and of record by Nutra Pharma’s shareholders.

G. Nutra Pharma has made available to Receptopharm all of its reports on file with the Securities and Exchange Commission, which reports reflect all of its audited and unaudited financial statements, all of its notes, mortgages and other obligations and agreements and other instruments for or relating to any borrowing effected by Nutra Pharma or to which any properties or assets of Nutra Pharma is subject, leases and similar agreements under which Nutra Pharma is subject, and a list of any and all contracts, agreements, and other instruments material to the conduct of Nutra Pharma’s business. Nutra Pharma has performed all obligations required by it to be performed under the any of the foregoing, and there has not occurred any event which with the passage of time or giving notice or both would constitute a
default. 

H. The execution, delivery and performance of this agreement by Nutra Pharma does not require the consent, waiver, approval, license or authorizations of any person or public authority which has not been obtained, does not violate, with or without the giving of notice or the passage of time or both, any law applicable to Nutra Pharma , and does not conflict with or result in a breach or termination of any provisions of, or constitute a default under, or result in the creation of any lien, charge or encumbrance upon any of the property or assets of Nutra Pharma . 

I. Nutra Pharma has complied with all laws, ordinances, regulations and orders which have application to its business, the violation of which might have a material adverse effect on its financial condition or results of operations, and possesses all governmental licenses and permits material to and necessary for the conduct of its business, the absence of which might have a material adverse effect on their respective financial condition or results of operations. All such licenses and permits are in full force and effect, no violations are or have been recorded in respect of any such licenses or permits, and no proceeding is pending or threatened to revoke or limit any such licenses or permits.

	 
	 	6	 
	

	 

J. All of the representations and warranties herein made by Nutra Pharma are applicable to it and to each of its subsidiaries as well.

K. There are no actions, suits, and proceedings pending or threatened against or affecting Nutra Pharma or its respective properties, business, or subsidiaries, at law or in equity and before or by any federal, state or other governmental body or any arbitration board, domestic or foreign. Nutra Pharma has no knowledge or notice of, any grounds for any other action, suit or proceeding.

8. CLOSING

Concurrently with the Closing, Receptopharm shall issue and deliver to Nutra Pharma certificates representing 2,777,778 shares of its issued and outstanding common stock, and Nutra Pharma shall deliver to Receptopharm an assignment of its license to the intellectual property specified in Attachment 1. The closing shall take place at the offices of Nutra Pharma on or before 7 days after the execution of this agreement.

Additional Receptopharm certificates shall be issued to Nutra Pharma as follows:

1.    As payments are received from Nutra Pharma, on the last day of each calendar quarter, Receptopharm shall issue one stock certificate to Nutra Pharma which shall represent the total number of shares purchased during the calendar quarter. Purchase price will be $0.45/share.

This agreement is contingent upon the approval of both company’s Board of Directors.

9. DEFAULT

In the event of a default on the attached payment schedule (Attachment 2), both company’s CEO’s will be notified by E-mail and by telephone messages. If the default is not corrected within 7 days after notification, this agreement can be terminated.

10. MISCELLANEOUS PROVISIONS:

This agreement shall be construed in accordance with the laws of the State of Florida.

This agreement shall be binding upon and shall inure to the benefit of the parties hereto, their beneficiaries, heirs, representatives, assigns, and all other successors in interest.

	 
	 	7	 
	

	 

Each of the parties shall execute any and all documents required to be executed and perform all acts required to be performed in order to effectuate the terms of this agreement.

This agreement contains all of the agreements and understandings of the parties hereto with respect to the matters referred to herein, and no prior agreement or understanding pertaining to any such matters shall be effective for any purpose.

Each of the parties hereto has agreed to the use of the particular language of the provisions of this Agreement, and any question of doubtful interpretation shall not be resolved by any rule of interpretation against the party who causes the uncertainty to exist or against the draftsman.

This agreement may not be superseded, amended or added to except by an agreement in writing, signed by the parties hereto, or their respective successors-in-interest.

Any waiver of any provision of this agreement shall not be deemed a waiver of such provision as to any prior or subsequent breach of the same provision or any other breach of any other provision of this agreement.

If any provision of this agreement is held, by a court of competent jurisdiction, to be invalid, or unenforceable, said provisions shall be deemed deleted, and neither such provision, its severance or deletion shall affect the validity of the remaining provisions of this agreement, which shall, nevertheless, continue in full force and effect.

The parties may execute this agreement in two or more counterparts, each of which shall be signed by all of the parties; and each such counterpart shall be deemed an original instrument as against any party who has signed it.

The parties shall use their reasonable best efforts to obtain the consent of all necessary persons and agencies to the transfer of shares provided for in this agreement.

Each party shall bear their own attorney’s fees and costs with respect to their due diligence and review of this Agreement. Nutra Pharma shall bear all the costs associated with the acquisition of the shares, including any SEC filings, state filings, and disclosures.

 

	 
	 	8	 
	

	 

IN WITNESS WHEREOF, the parties have executed this agreement as of the day and year first above written.

	 	 	 
	 	Nutra Pharma Corp.
	 
 	 
 	 
 
		By:  	/s/ Rik Deitsch
	 	

RIK DEITSCH, President and Chief Executive Officer
	 	

	 	 	 
	 	Receptopharm, Inc.
	 
 	 
 	 
 
		By:  	/s/ Harold H, Rumph
	 	

HAROLD H. RUMPH, President
	 	Title 

 

	 
	 	9	 
	

	 

ATTACHMENT 1

	
U.S. Patent Application for POLYPEPTIDE COMPOSITIONS AND METHODS

	 	
ISSUED
	 	 
	 	
Filed
	
8/7/97
	
Serial No. 08/908,212

	 	
Issued
	
11/23/99
	
Patent No. 5,989,857

	 	 	 	 
	 	
 

U.S. Patent Application for POLYPEPTIDE COMPOSITIONS AND METHODS
	 
	 	
PENDING
	 	 
	 	
Filed
	
8/5/99
	
Serial No. 09/368,834

	 	 	 	 
	 	
 

U.S. Patent Application for POLYPEPTIDE COMPOSITIONS AND METHODS
	 
	 	
PENDING
	 	 
	 	
Filed
	
11/7/02
	
Serial No. 10/289,834

	 	 	 	 
	 	
 

U.S. Patent Application for IMMUNOKINE COMPOSITION AND METHOD
	 
	 	
PENDING
	 	 
	 	
Filed
	
March 23, 2000
	
Serial No. 09/533,454

	 	 	 	 
	 	
 

U.S. Patent Application for IMMUNOKINE COMPOSITION AND METHOD
	 
	 	
PENDING
	 	 
	 	
Filed
	
November 12, 2002
	
Serial No. 10/292,164

	 	 	 	 
	 	
 

U.S. Patent Application for BUCCAL DELIVERY SYSTEM
	 
	 	
PENDING
	 	 
	 	
Filed
	
January 28, 2000
	
Serial No. 009070632

 

	 
	 	10	 
	

	 

ATTACHMENT 2

	
Total from Nutra Pharma Corp
	
$750,000

	
01/15/05 $200K

02/15/05 $150K 

03/15/05 $150K

04/15/05 $250K
	 

 

 

 

ATTACHMENT 3

Proprietary Property

3 patents applications:

	1.  	MODIFIED ANTICHOLINERGIC NEUROTOXINS AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS. Utility application, claims the use of such peptides as useful for the treatment of neurological disorders in general where improved nerve conduction would be useful and as a vaccine. Diseases include AMN.

	2.  	MODIFIED ALPHA-NEUROTOXINS AS PAINKILLERS. Provisional Application. Claims the use of modified alpha-neurotoxins in the control of pain

	3.  	MODIFIED VENOM AND VENOM COMPONENTS AS ANTI-RETROVIRAL AGENTS. Provisional Application. Claims the modified venom and peptides thereof for the treatment of HIV and other retroviruses.

Patent Lawyer

Robert J. Van Der Wall, P.A., 

First Union Financial Center, Suite 5100, 

200 South Biscayne Boulevard, 

Miami, FL 33131-2310 

Tel: (305) 358-600

 

	 
	 	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]